Guangzhou Baiyunshan Pharmaceutical Holdings (00874) received the approval notice for the application of listing of chemical raw materials.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced recently that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Medical Group Co., Ltd. (hereinafter referred to as the Company), received approval from the National Medical Products Administration for the listing application of atorvastatin calcium for chemical raw materials. Atorvastatin calcium is a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. It mainly works by inhibiting the synthesis of HMGCoA reductase, thereby reducing the synthesis of cholesterol in the body and lowering the levels of serum low-density lipoprotein cholesterol and triglycerides. It is mainly used for primary hypercholesterolemia, mixed hyperlipidemia, hypertriglyceridemia, homozygous familial hypercholesterolemia, and the prevention and treatment of atherosclerosis. Currently, the main manufacturers of atorvastatin calcium raw materials in China are Qilu Pharmaceutical Co., Ltd., Tianfang Pharmaceutical Co., Ltd., and Yichang HEC CJ PHARM Co., Ltd. According to the data from Minet, the sales of atorvastatin calcium tablets in Chinese public hospitals and retail pharmacies in 2023 amounted to RMB 6,374.74 million.